Erratum: Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: A potential role in reducing the duration of treatment (J Antimicrob Chemother (2015) 70: (3107–3115) DOI: 10.1093/jac/dkv241);Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: A potential role in reducing the duration of treatment

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 3107-3115

  Martínez Jiménez, M Carmen ^a   Muñoz, Patricia ^a,b,c   Valerio, Maricela ^a   Vena, Antonio ^a   Guinea, Jesús ^a,b   Bouza, Emilio ^a,b,c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BETA GLUCAN; BIOLOGICAL MARKER; ECHINOCANDIN; FUNGUS ANTIBODY; BETA-1,3-D-GLUCAN;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BETA DEXTRO GLUCAN TEST; BLOOD SAMPLING; CANDIDA ALBICANS; CANDIDA ALBICANS GERM TUBE ANTIBODY TEST; CANDIDEMIA; DRUG INDICATION; FEMALE; GASTROINTESTINAL SURGERY; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; INFECTION RISK; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEPSIS; SPAIN; TERTIARY CARE CENTER; TREATMENT DURATION; VEIN PUNCTURE; WARD; AGED; BLOOD; CANDIDIASIS, INVASIVE; DRUG EFFECTS; INTENSIVE CARE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, FUNGAL; ANTIFUNGAL AGENTS; BETA-GLUCANS; BIOMARKERS; CANDIDA ALBICANS; CANDIDIASIS, INVASIVE; CRITICAL CARE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPAIN; TERTIARY CARE CENTERS;

EID: 84949034610     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw193     Document Type: Erratum

References (41)

1. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
2. Clancy CJ, Nguyen MH. Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies. Expert Rev Anti Infect Ther 2014; 12: 731-4.
3. Azoulay E, Dupont H, Tabah A et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit Care Med 2012; 40: 813-22.
4. Lam SW, Eschenauer GA, Carver PL. Evolving role of early antifungals in the adult intensive care unit. Crit Care Med 2009; 37: 1580-93.
5. Mohr JF, Sims C, Paetznick V et al. Prospective survey of (1→3)-ß-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011; 49: 58-61.
6. Leon C, Ruiz-Santana S, Saavedra P et al. Value of ß-D-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive Care Med 2012; 38: 1315-25.
7. Tissot F, Lamoth F, Hauser PM et al. ß-Glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 2013; 188: 1100-9.
8. Ponton J, del Palacio A. [Advances and limitations in the early diagnosis of invasive yeast infections.] Rev Iberoam Micol 2007; 24: 181-6.
9. Martínez-Jiménez MC, Muñoz P, Valerio M et al. Candida biomarkers in patients with candidaemia and bacteraemia. J Antimicrob Chemother 2015; 70: 2354-61.
10. Cornely OA, Bassetti M, Calandra T et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18 Suppl 7: 19-37.
11. Cuenca-Estrella M, Verweij PE, Arendrup MC et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18 Suppl 7: 9-18.
12. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
13. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
14. Lo Cascio G, Koncan R, Stringari G et al. Interference of confounding factors on the use of (1,3)-ß-D-glucan in the diagnosis of invasive candidiasis in the intensive care unit. Eur J Clin Microbiol Infect Dis 2015; 34: 357-65.
15. Pickering JW, Sant HW, Bowles CA et al. Evaluation of a (1→3)-ß-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-62.
16. Hanson KE, Pfeiffer CD, Lease ED et al. ß-D-Glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 2012; 7: e42282.
17. Ogawa M, Hori H, Niiguchi S et al. False-positive plasma (1→3)-ß-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. Int J Hematol 2004; 80: 97-8.
18. Marty FM, Koo S. Role of (1→3)-ß-D-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47 Suppl 1: S233-40.
19. Mennink-Kersten MA, Warris A, Verweij PE. 1,3-ß-D-Glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354: 2834-5.
20. Racil Z, Kocmanova I, Lengerova M et al. Difficulties in using 1,3-ß-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies-high frequency of false-positive results and their analysis. J Med Microbiol 2010; 59: 1016-22.
21. Nagasawa K, Yano T, Kitabayashi G et al. Experimental proof of contamination of blood components by (1→3)-ß-D-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs 2003; 6: 49-54.
22. Usami M, Ohata A, Horiuchi T et al. Positive (1→3)-ß-D-glucan in blood components and release of (1→3)-ß-D-glucan from depth-type membrane filters for blood processing. Transfusion 2002; 42: 1189-95.
23. Racil Z, Kocmanova I, Toskova M et al. Reactivity of the 1,3-ß-D-glucan assay during bacteraemia: limited evidence from a prospective study. Mycoses 2013; 56: 101-4.
24. Eggimann P, Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med 2014; 40: 1429-48.
25. Leon C, Ostrosky-Zeichner L, Schuster M. What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med 2014; 40: 808-19.
26. Bassetti M, Marchetti M, Chakrabarti A et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 2013; 39: 2092-106.
27. Leroy O, Gangneux JP, Montravers P et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-8.
28. Olaechea-Astigarraga PM, Alvarez-Lerma F, Palomar-Martinez M et al. [Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006-2010.] Enferm Infecc Microbiol Clin 2012; 30: 435-40.
29. Valerio M, Rodriguez-Gonzalez CG, Munoz P et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother 2014; 69: 1993-9.
30. Ruhnke M. Antifungal stewardship in invasive Candida infections. Clin Microbiol Infect 2014; 20 Suppl 6: 11-8.
31. Bruyere R, Quenot JP, Prin S et al. Empirical antifungal therapy with an echinocandin in critically-ill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU. BMC Infect Dis 2014; 14: 385.
32. Bassetti M, Molinari MP, Mussap M et al. Candidaemia in internal medicine departments: the burden of a rising problem. Clin Microbiol Infect 2013; 19: E281-4.
33. Martinez-Jimenez MC, Munoz P, Guinea J et al. Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia. Med Mycol 2014; 52: 270-5.
34. Ma CF, Li FQ, Shi LN et al. Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China. BMC Infect Dis 2013; 13: 337.
35. Falcone M, Concia E, Iori I et al. Identification and management of invasive mycoses in internal medicine: a road-map for physicians. Intern Emerg Med 2014; 9: 501-11.
36. Tortorano AM, Prigitano A, Lazzarini C et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection 2013; 41: 655-62.
37. Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: hownonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013; 56: 1284-92.
38. Mikulska M, Furfaro E, Viscoli C. Non-cultural methods for the diagnosis of invasive fungal disease. Expert Rev Anti Infect Ther 2014; 13: 1-15.
39. Zaragoza R, Peman J, Quindos G et al. Kinetic patterns of Candida albicans germ tube antibody in critically ill patients: influence on mortality. Clin Vaccine Immunol 2009; 16: 1527-8.
40. Pazos C, Moragues MD, Quindos G et al. Diagnostic potential of (1,3)-ß-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol 2006; 23: 209-15.
41. Lenz P, Eckelskemper F, Erichsen Tet al. Prospective observational multicenter study to define a diagnostic algorithm for biliary candidiasis.World J Gastroenterol 2014; 20: 12260-8.